New IVD player Diaxonhit emerges from Exonhit's InGen purchase
This article was originally published in Clinica
Executive Summary
French biotech firm Exonhit Therapeutics is to acquire InGen Biosciences, a privately-held developer and distributor of IVD products, in a move that will give the former commercialisation clout in the diagnostics sector and significantly augment its revenue flow. The subsequent merger of the two companies will result in a new concern, to be named Diaxonhit.